A new study published in GEN - Genetic Engineering and Biotechnology News identifies brain-infiltrating γδ T cells as a driver of social deficits in a genetic autism mouse model. Accumulation of these immune cells in the brain was linked to reduced sociability, revealing a novel connection between the immune system and autism-related behaviors.
Researchers demonstrated that removing or blocking γδ T cells restored normal social behavior in the mice. The findings suggest that immune dysregulation may directly contribute to core symptoms of autism spectrum disorder (ASD), opening a new avenue for treatment development.
No clinical timeline is available, as the study is limited to preclinical animal models. Human trials would be required to confirm whether similar mechanisms operate in people with autism, and to evaluate safety and efficacy of immune-targeted therapies.
The discovery positions immune modulation as a potential therapeutic strategy for ASD, a condition that currently lacks disease-modifying drugs. If translatable to humans, it could expand treatment options for social deficits, though the path to the clinic remains long and uncertain.
"This is early-stage research," the authors caution. "While promising, the results in mice must be replicated and validated in human studies before any therapeutic conclusions can be drawn."